文献速递消化系统肿瘤头颈与中枢神经肿瘤

结直肠癌脑转移中的HER2扩增:一项倾向性评分匹配研究

HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study.
PubMed 文献 · Eur J Cancer · 2022-12-27

回顾性纳入99例伴脑转移的转移性结直肠癌患者与249例无脑转移的IV期患者,经倾向性评分匹配比较HER2扩增情况。脑转移队列HER2扩增16/87例(18.4%),IV期队列9/249例(3.6%),P<.001;匹配后HER2扩增与脑转移显著相关(OR 5.38,P=.003)。HER2异质性常见,脑转移后生存差异仅边缘显著(P=.07)。

要点

  • 脑转移队列HER2扩增率为18.4%(16/87),显著高于IV期无脑转移队列的3.6%(9/249),P<.001。
  • 倾向性评分匹配后,HER2扩增与脑转移显著相关,OR为5.38(P=.003)。
  • HER2异质性在单一肿瘤及配对肿瘤样本中均常见,建议对原发与转移灶可用组织均行HER2检测。

核心结论

  • 在转移性结直肠癌患者中,HER2扩增与脑转移显著相关,并可能对脑转移后生存具有预后价值。

研究设计与样本

  • 回顾性研究,纳入99例伴脑转移的转移性结直肠癌患者(脑转移队列),与249例无脑转移的IV期患者(IV期队列)经倾向性评分匹配比较。
  • 对所有可用石蜡包埋肿瘤样本(原发灶、转移灶或两者)行HER2免疫组化,必要时行荧光原位杂交。

主要发现

  • 脑转移队列有标本可检测的87例中16例(18.4%)检出HER2扩增,IV期队列249例中9例(3.6%)检出,P<.001。
  • 倾向性评分匹配后,HER2扩增与脑转移显著相关,比值比为5.38,P=.003。
  • HER2异质性在单一肿瘤水平及配对肿瘤样本中均常见。
  • HER2扩增的转移性结直肠癌患者自脑转移起生存较无扩增者边缘显著延长,P=.07。

关键数值与推荐

  • HER2扩增定义依据免疫组化及必要时荧光原位杂交检测结果。
  • 脑转移队列HER2扩增16/87例(18.4%),IV期队列9/249例(3.6%),P<.001。
  • 匹配后HER2扩增与脑转移的比值比为5.38,P=.003。
  • 自脑转移起生存比较P=.07。

临床怎么用

  • 鉴于HER2表达异质性,作者鼓励对原发肿瘤与转移肿瘤的可用组织均进行HER2状态检测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The association between human epidermal growth factor receptor-2 (HER2) amplification and brain metastasis (BM) in patients having colorectal cancer (CRC) has been suggested but not yet established. This study investigated the expression patterns of HER2, its association with BM, and its prognostic value in patients having CRC. METHODS: We retrospectively identified 99 patients having metastatic CRC (mCRC) and BM (the BM cohort) and compared them with a cohort of 249 patients having mCRC and without BM (the stage IV cohort) by propensity score matching. Immunohistochemical studies of HER2 on all available paraffin-embedded tumour samples, either from the primary tumour, the metastasis (brain and/or extracranial sites) or both, were performed and analysed. HER2 fluorescent in situ hybridisation was applied when necessary. The expression of HER2 was compared and correlated with survival. RESULTS: HER2 amplifications were detected in 16 (18.4%) of 87 and 9 (3.6%) of 249 patients who had specimens available in the BM and stage IV cohorts, respectively (P < .001). After propensity score matching, HER2 amplification was significantly associated with BM (odds ratio: 5.38, P = .003). HER2 heterogeneity was frequently observed not only at the single tumour level but also in paired tumour samples. A marginally significant longer survival since BM was found in patients having HER2-amplified mCRC than in those without (P = .07). CONCLUSIONS: HER2 amplification was significantly associated with BM in patients having mCRC and might have prognostic value for survival since BM. Given the heterogeneity of HER2 expression, the testing of HER2 status on available tissues from both primary and metastatic tumours should be encouraged.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Chen PC, Yeh YM, Chu CT, et al. HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study. Eur J Cancer. 2022. PMID: 36640475. doi:10.1016/j.ejca.2022.12.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。